Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $11,768.30 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 1,718 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $6.85, for a total transaction of $11,768.30. Following the completion of the sale, the director owned 2,846,592 shares in the company, valued at approximately $19,499,155.20. The trade was a 0.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Kush Parmar also recently made the following trade(s):

• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.93, for a total transaction of $795,259.08.

Entrada Therapeutics Price Performance

NASDAQ TRDA opened at $7.06 on Thursday. The company’s fifty day moving average is $6.86 and its two-hundred day moving average is $9.77. Entrada Therapeutics, Inc. has a 52-week low of $4.93 and a 52-week high of $16.45. The firm has a market capitalization of $274.07 million, a price-to-earnings ratio of -1.77 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.03. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.23 million. As a group, sell-side analysts expect that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Entrada Therapeutics

Several large investors have recently modified their holdings of the stock. State of Wyoming raised its holdings in shares of Entrada Therapeutics by 130.9% in the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after buying an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after buying an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics in the second quarter valued at $68,000. IHT Wealth Management LLC bought a new stake in Entrada Therapeutics in the second quarter valued at $72,000. Finally, Jain Global LLC acquired a new position in Entrada Therapeutics during the third quarter worth $69,000. 86.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TRDA has been the subject of a number of recent research reports. Weiss Ratings lowered Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. Guggenheim lowered their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Roth Capital set a $10.00 price objective on shares of Entrada Therapeutics in a research note on Friday, May 8th. Finally, HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $17.50.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.